Taysha Gene Therapies, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Taysha Gene Therapies, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $691.00K, a 471.07% increase year-over-year.
- Taysha Gene Therapies, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $516.00K.
- Taysha Gene Therapies, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $1.02M.
- Taysha Gene Therapies, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $76.00K, a 100.00% increase year-over-year.
- Taysha Gene Therapies, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $1.22M, a 2950.00% increase from fiscal 2024.
- Taysha Gene Therapies, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $40.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $691.00K 10-Q · filed 2026-08-11 | $2.31M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $516.00K 10-Q · filed 2026-05-06 | $1.74M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.22M 10-K · filed 2026-03-19 |
| 2025-09-30 | $76.00K 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $121.00K 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $40.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $38.00K 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $2.00K 10-Q · filed 2024-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |